Abstract
The efficacy of aspirin to prevent ischemic cardiovascular disease has received considerable attention recently. To determine the prevalence of aspirin use for cardiovascular disease prevention, the Minnesota Heart Survey examined population-based samples of Twin Cities' adults in 1981 to 82 and 1985 to 86. Over the 4-year period, reported use of aspirin for cardiovascular disease prophylaxis increased from 0.6% to 2.4% in women ( p < 0.05) and from 1.7% to 3.3% in men ( p = 0.10). Prophylactic aspirin use was more common in older than in younger adults, in whites than in blacks, in those with a history of cardiovascular disease or hypercholesterolemia, and in health professionals and nonsmokers. Some individuals were apparently taking aspirin for “primary” prevention, although it has not yet been approved for that reason. Use of aspirin for cardiovascular disease prevention has been increasing and is likely to increase more rapidly over the next few years. This could favorably impact on mortality rates of cardiovascular disease, but untoward side effects of aspirin may be expected to increase as well.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.